General Assembly
Vienna, 13 June 2016
Antonella Muraro
EAACI President 2015-2017
Practice:
*Allergen Immunotherapy Guidelines – AIT*

Science:
*Precision Medicine in allergic diseases*

Internal:
*Governance*

External:
*Lobbying Activities for Specialty*
Best Practice Guidelines

Food allergy and anaphylaxis
Guidelines for Clinical Practice

ALLERGEN IMMUNOTHERAPY GUIDELINES
FOR CLINICAL PRACTICE
June, 2017

- Will support health care professionals’ use of AIT
- Will highlight benefits at public and policy maker levels
- Will promote health economics of AIT
Allergen Immunotherapy Guidelines

**Aim:** generate evidence-based guidelines for allergen immunotherapy

**Steering Committee:** President, BoO, ExCom

**Task Forces:** 7 (embracing all relevant stakeholders i.e. clinicians, basic scientists, patient organizations, regulatory bodies representatives, allied health representatives worldwide)

- ARC - Asthma - Food
- Venom - Prevention - Primary Care
- Allergen Manufacturing/Regulatory bodies issues
Allergen Immunotherapy Guidelines

Methodologists’ group (led by Aziz Sheikh)

Current status:
- Preparing **five systematic reviews** to generate evidence for guidelines:
  - Venom – draft complete
  - Rhinoconjunctivitis – ongoing
  - Prevention – draft complete
  - Asthma – ongoing
  - Food allergy – ongoing
- Position papers focusing on primary care and regulations in development

Planned activities 2016-2017
- Finalise systematic reviews, summer – autumn 2016.
- Finalise draft guidelines early 2017 – will be available for comment before they are finalised and published in June 2017.
Science: PRACTALL

Precision Medicine in Allergic Diseases

1- Airways Diseases and Atopic Dermatitis
   (JACI, May 2016)

2- Food Allergy, Drug Allergy and Anaphylaxis
   (ALLERGY, October 2016)

- ‘One size fits all’ approach
- ‘Trial and error’ approach
- Suppression of symptoms
- Paternalistic approach

- Personalized care
- Prediction of success
- Prevention (prim/sec/tert)
- Participation of patient

APPLICABLE TO ALLERGIES AIRWAYS DISEASES
Internal: Governance

- Framing **EAACI's governance** and organisational design to be fit for purpose for the next decade

- **Revision** of the **Bylaws** and of the **Constitution** by February 2017 to be submitted to the General Assembly by June 2017
External: Lobbying at EU

- EU Liaison Office
- Policy events of the MEP Interest Group in EU Parliament (17 MEP)
- European Symposium on Precision Medicine in Allergy and Airways Disease
- Event on Allergic disease at the EU Parliament, April 2016
- AIT Summit November 2016
- High Level EU Business lunch at the Annual Congress
Member of key EU health stakeholders alliances:

- European Chronic Disease Alliance (ECDA)
- Alliance for Biomedical Research in Europe (BioMed Alliance)

Close collaborations:

- WHO Europe
- European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)
- European Medicines Agency (EMA)
Dedicated to allergy science, committed to your health
HEAD QUARTER up-date

New Executive Director: Mrs Sue Paredi

New Position:
Manager for Publications, Relations and Public Affairs
Mrs Lena Geltenbort-Rost

GOVERNANCE PROJECT

Time-lines:
- BoO meeting, July 8, 2016
- BoO and ExCom meeting Sept 8-11, 2016
- Revision of Bylaws by Dec 2016
- Revision of Constitution by Feb 2017
- Approval by GA in June 2017
EAACI or EAAACI Voting Report
EAACI or EAAACI?
Total Votes: 1885

Voting closed 05.02.16
EAACI or EAAACI? Pros & Cons

981 YES
904 NO
Election of **EAACI President 2017-2019:**

Nomination of Executive Committee:

Ioana Agache, VP Communication
INTERNAL AFFAIRS

APPROVAL
of
SECRETARY GENERAL REPORT
Capital invested at ZKB
Development of Market Value

<table>
<thead>
<tr>
<th>Year</th>
<th>Nominal Capital</th>
<th>Market Value at End of Year</th>
<th>Interest received</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>1360</td>
<td>1,454</td>
<td>78.3</td>
</tr>
<tr>
<td>2011</td>
<td>2310</td>
<td>2,477</td>
<td>80.7</td>
</tr>
<tr>
<td>2012</td>
<td>2550</td>
<td>2,797</td>
<td>101.1</td>
</tr>
<tr>
<td>2013</td>
<td>2950</td>
<td>3,251</td>
<td>116.7</td>
</tr>
<tr>
<td>2014</td>
<td>2950</td>
<td>3,325</td>
<td>115.4</td>
</tr>
<tr>
<td>2015</td>
<td>3040</td>
<td>3,193</td>
<td>106.8</td>
</tr>
</tbody>
</table>

Interest received in %       5.76%  3.49%  3.96%  3.96%  3.91%  3.51%
## Income 2015

<table>
<thead>
<tr>
<th>Category</th>
<th>Dec 31st 2015</th>
<th>Budget 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>'000 €</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Founder &amp; Corporate Sponsors</td>
<td>1'504.7</td>
<td>1'399.4</td>
</tr>
<tr>
<td>Congress &amp; Focussed Meeting</td>
<td>1'894.5</td>
<td>1'400.0</td>
</tr>
<tr>
<td>Membership Subscription</td>
<td>328.2</td>
<td>310.0</td>
</tr>
<tr>
<td>Communication Activities</td>
<td>125.9</td>
<td>115.5</td>
</tr>
<tr>
<td>Education</td>
<td>24.9</td>
<td>74.0</td>
</tr>
<tr>
<td>Fundraising Concept</td>
<td>65.0</td>
<td>65.0</td>
</tr>
<tr>
<td>Other Income</td>
<td>41.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Interest</td>
<td>106.8</td>
<td>102.1</td>
</tr>
<tr>
<td>Extraordinary Income</td>
<td>136.5</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>Total Income 2015</strong></td>
<td><strong>4'227.5</strong></td>
<td><strong>3'466.0</strong></td>
</tr>
</tbody>
</table>

General Assembly, Vienna 2016
Treasurer: Marek Jutel
## Expenses 2015

<table>
<thead>
<tr>
<th>Category</th>
<th>Dec 31st 2015</th>
<th>Budget 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congresses &amp; Focussed Meeting</td>
<td>103.2</td>
<td>40.0</td>
</tr>
<tr>
<td>Task Forces and new projects</td>
<td>517.6</td>
<td>815.8</td>
</tr>
<tr>
<td>Communication &amp; Membership</td>
<td>436.9</td>
<td>451.0</td>
</tr>
<tr>
<td>Education</td>
<td>400.2</td>
<td>541.8</td>
</tr>
<tr>
<td>External Strategic Activities</td>
<td>222.2</td>
<td>212.0</td>
</tr>
<tr>
<td>Administration &amp; ExCom</td>
<td>638.1</td>
<td>541.5</td>
</tr>
<tr>
<td>Headquarters Zurich</td>
<td>1'374.7</td>
<td>1'220.5</td>
</tr>
<tr>
<td>Organization growth / Other</td>
<td>111.9</td>
<td>44.8</td>
</tr>
<tr>
<td>Contingency / Extraordinary</td>
<td>397.9</td>
<td>50.0</td>
</tr>
<tr>
<td><strong>Total Expenses 2015</strong></td>
<td><strong>4'202.7</strong></td>
<td><strong>3'917.4</strong></td>
</tr>
</tbody>
</table>
### Surplus / -Deficit 2015

<table>
<thead>
<tr>
<th></th>
<th>Dec 31st 2015</th>
<th>Budget 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total of Income</td>
<td>4'227.5</td>
<td>3'466.0</td>
</tr>
<tr>
<td>Total of Expenses</td>
<td>-4'202.7</td>
<td>-3'917.4</td>
</tr>
<tr>
<td>Surplus/-Deficit 2015</td>
<td>24.8</td>
<td>-451.4</td>
</tr>
<tr>
<td>Adjustment investment to market value</td>
<td>-228.4</td>
<td></td>
</tr>
<tr>
<td>Deficit 2015 audited</td>
<td>-203.6</td>
<td></td>
</tr>
</tbody>
</table>
## Income 2016
(Budget)

<table>
<thead>
<tr>
<th>Source</th>
<th>Budget 2016 '000 €</th>
</tr>
</thead>
<tbody>
<tr>
<td>Founder &amp; Corporate Sponsors</td>
<td>1'885.8</td>
</tr>
<tr>
<td>Congress &amp; Focussed Meeting</td>
<td>1'490.0</td>
</tr>
<tr>
<td>Membership Subscription</td>
<td>320.0</td>
</tr>
<tr>
<td>Communication Activities</td>
<td>145.0</td>
</tr>
<tr>
<td>Education</td>
<td>19.0</td>
</tr>
<tr>
<td>Fundraising Concept</td>
<td>50.0</td>
</tr>
<tr>
<td>Other Income</td>
<td>30.0</td>
</tr>
<tr>
<td>Interest</td>
<td>93.0</td>
</tr>
<tr>
<td>Extraordinary Income</td>
<td>300.0</td>
</tr>
<tr>
<td><strong>Total Budget Income 2016</strong></td>
<td><strong>4'332.8</strong></td>
</tr>
</tbody>
</table>

General Assembly, Vienna 2016  
Treasurer: Marek Jutel
# Expenses 2016
(Budget)

<table>
<thead>
<tr>
<th>Expenses</th>
<th>Budget 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>'000 €</td>
<td></td>
</tr>
<tr>
<td>Congresses &amp; Focussed Meetings</td>
<td>40.0</td>
</tr>
<tr>
<td>Task Forces and new projects</td>
<td>847.4</td>
</tr>
<tr>
<td>Communication &amp; Membership</td>
<td>868.0</td>
</tr>
<tr>
<td>Education</td>
<td>578.1</td>
</tr>
<tr>
<td>External Strategic Activities</td>
<td>135.0</td>
</tr>
<tr>
<td>Administration &amp; ExCom</td>
<td>623.5</td>
</tr>
<tr>
<td>Headquarters Zurich</td>
<td>1'719.8</td>
</tr>
<tr>
<td>Organization Growth &amp; Other</td>
<td>113.9</td>
</tr>
<tr>
<td>Miscellaneous / Contingency</td>
<td>50.0</td>
</tr>
</tbody>
</table>
| **Total Budget Expenses 2016**              | **4'975.7** }
## Surplus /-Deficit 2016
(Budget)

<table>
<thead>
<tr>
<th></th>
<th>Budget 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total of Income</td>
<td>4'332.8</td>
</tr>
<tr>
<td>Total of Expenses</td>
<td>-4'975.7</td>
</tr>
<tr>
<td>Deficit 2016</td>
<td>-642.9</td>
</tr>
<tr>
<td>Projects on hold</td>
<td>-82.3</td>
</tr>
<tr>
<td>Deficit 2016 with Project on hold</td>
<td>-725.2</td>
</tr>
</tbody>
</table>
Projection accumulated profit over the years

<table>
<thead>
<tr>
<th>'000 €</th>
<th>as of 31.12.</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2016 projection</td>
<td>3'155.7</td>
</tr>
<tr>
<td>December 2015</td>
<td>3'790.5</td>
</tr>
<tr>
<td>December 2014</td>
<td>3'994.1</td>
</tr>
<tr>
<td>December 2013</td>
<td>2'862.4</td>
</tr>
<tr>
<td>December 2012</td>
<td>3'247.3</td>
</tr>
<tr>
<td>December 2011</td>
<td>3'192.2</td>
</tr>
<tr>
<td>December 2010</td>
<td>2'677.3</td>
</tr>
<tr>
<td>December 2009</td>
<td>2'658.8</td>
</tr>
<tr>
<td>December 2008</td>
<td>2'270.0</td>
</tr>
</tbody>
</table>

Capital as of 31.12.2015: 3'790.5
Deficit 2016 Budget: -552.5
Project on hold Budget: -82.3
Projected capital as of 31.12.2016: 3'155.7
# Financial Status

## Development of Income and Expenses

**ExCom Meeting Vienna 2016**

Treasurer: Marek Jutel

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Income</th>
<th>Total Expenses</th>
<th>Surplus/-Deficit</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>2,415.4</td>
<td>2,085.7</td>
<td>329.7</td>
</tr>
<tr>
<td>2009</td>
<td>2,955.7</td>
<td>2,567.0</td>
<td>388.7</td>
</tr>
<tr>
<td>2010</td>
<td>3,548.9</td>
<td>3,431.3</td>
<td>117.6</td>
</tr>
<tr>
<td>2011</td>
<td>3,682.8</td>
<td>3,167.8</td>
<td>515.0</td>
</tr>
<tr>
<td>2012</td>
<td>3,091.8</td>
<td>3,036.7</td>
<td>55.1</td>
</tr>
<tr>
<td>2013</td>
<td>3,106.3</td>
<td>3,414.6</td>
<td>-308.3</td>
</tr>
<tr>
<td>2014</td>
<td>3,784.0</td>
<td>2,726.7</td>
<td>1,057.4</td>
</tr>
<tr>
<td>2015</td>
<td>4,227.5</td>
<td>4,202.7</td>
<td>24.8</td>
</tr>
</tbody>
</table>
Audit Report 2015

Report of the mandatory auditors to the management of

European Academy of Allergy and Clinical Immunology, Zürich

As mandatory auditors, we have audited the financial statements (balance sheet and income statement) of European Academy of Allergy and Clinical Immunology for the year ended 31 December 2015.

These financial statements (balance sheet and income statement) are the responsibility of the board of directors.

Our responsibility is to express an opinion on these financial statements based on our audit. Our audit was conducted in accordance with auditing standards promulgated by the Swiss profession, which require that an audit be planned and performed to obtain reasonable assurance about whether the financial statements are free from material misstatement. We have examined on a test basis evidence supporting the amounts and disclosures in the financial statements. We have also assessed the accounting principles used, significant estimates made and the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the accounting records and financial statements (balance sheet and income statement) comply with Swiss law.

5405 Baden, May 25, 2016

MERKLI & PARTNER AG

Christian Feller
Licensed Audit Expert

Benjamin Merki
Licensed Audit Expert
Approval of Treasurer Report
# Update Vienna Registrations

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Attendees</strong></td>
<td>7,874</td>
<td>6,217</td>
<td>7,694</td>
<td>7,403</td>
<td>7,667</td>
<td>7,363</td>
</tr>
<tr>
<td><strong>Abstracts</strong></td>
<td>1,932</td>
<td>1,684</td>
<td>2,150</td>
<td>1,987</td>
<td>1,968</td>
<td>1,869</td>
</tr>
</tbody>
</table>
EAACI Congress 2016
Dancing with Allergens

**Constant improvement:** Data collection with tags for 2000 delegates – to assess anonymously the attractiveness of sessions and congress areas

**Clinical Village:** established in 2014, 14 stations in Vienna
**National Society Village:** 19 Societies present themselves

**EAACI 60 years activities:** Visit the exhibition

**Beat Allergy Run:** donation to Clemens von Pirquet Foundation

**Opt-out** of bag and programme possible – going green

**Digital events:** Livestreaming with moderation to the global community, improved app features, Virtual Congress Hub
EAACI Congress 2017
Helsinki, Finland
Congress Chair: Antti Lauerman

European Academy of Allergy and Clinical Immunology
17 – 21 June 2017
Helsinki, Finland

Visit the website for more information

www.eaaci.org  #eaaci2017
EAACI Congresses 2018 and 2019

2018: Munich, Germany
Congress Chair: Carsten Schmidt-Weber

2019: Lisbon, Portugal
Congress Chair: Luis Delgado
Focused Meetings
FM conducted since last GA

4th Pediatric Allergy and Asthma Meeting (PAAM 2015), Berlin
More than 1300 attendees

6th International Symposium on Molecular Allergology (ISMA 2015), Lisbon
More than 300 delegates from 37 countries

7th Drug Hypersensitivity Meeting, Malaga
More than 500 delegates from 51 countries
Upcoming Focused Meetings 2016

4th Food Allergy and Anaphylaxis Meeting (FAAM 2016) 13 – 15 October 2016, Rome
Chairs: Antonella Muraro, Clare Mills

9th EuroBAT Meeting - The European Consortium on Application of Flow Cytometry in Allergy
12 October 2016 - In conjunction with FAAM 2016
Chair: Bernadette Eberlein

3rd International Severe Asthma Forum (ISAF 2016) 17 – 19 November 2016, Manchester
Chairs: Ömer Kalayci, Angela Simpson
Upcoming Focused Meetings 2017

11th Symposium on Experimental Rhinology and Immunology of the Nose (SERIN 2017)
30 March – 1 April 2017, Düsseldorf
Chairs: Ralph Mösges, Martin Wagenmann

Skin Allergy Meeting (SAM 2017)
27 – 29 April 2017, Zurich, In collaboration with ESCD
Chairs: Carsten Bindslev-Jensen, Peter Schmid-Grendelmeier, Magnus Bruze

5th Pediatric Allergy and Asthma Meeting (PAAM 2017), 26 – 29 October 2017, London
Chairs: George du Toit, Montserrat Alvaro Lozano, Lauri-Ann van der Poel

7th International Symposium on Molecular Allergology (ISMA 2017), 9 – 11 November 2017, Luxemburg
Chair: Markus Ollert
Fellowships

8 years of supporting JM in their professional development:

140 winners from 38 countries:
  89 Research fellowships
  51 Clinical Fellowships

Online application

Robust and independent review process taking into account Conflicts of Interest and reviewer’s specific expertise

→ Applications each year October - December
Research Fellowships 2016

Long Term

Sebastian Bode
Nonhlanhla Lunjani
Heleen Vroman
Maria Doulaptsi
Ekaterina Khaleva

Medium Term

Peter Valentin Tomazic
Hern Tze Tina Tan
Laura Martín Pedraza

Short Term

Judit Fazekas
Joana Gomes Belo
Natalia Aliakhnovich
<table>
<thead>
<tr>
<th>Country</th>
<th>Candidates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Switzerland</td>
<td>63</td>
</tr>
<tr>
<td>Greece</td>
<td>50</td>
</tr>
<tr>
<td>Spain</td>
<td>49</td>
</tr>
<tr>
<td>Turkey</td>
<td>24</td>
</tr>
<tr>
<td>Germany</td>
<td>16</td>
</tr>
<tr>
<td>UK</td>
<td>14</td>
</tr>
<tr>
<td>Romania, Slovenia, France</td>
<td>13</td>
</tr>
<tr>
<td>Italy, Netherlands</td>
<td>12</td>
</tr>
<tr>
<td>Belgium, Czech Republic, Poland, Russia</td>
<td>9</td>
</tr>
<tr>
<td>India, Ireland, Saudi Arabia, Slovakia, South Africa, UAE</td>
<td>7</td>
</tr>
<tr>
<td>Austria</td>
<td>5</td>
</tr>
<tr>
<td>Australia, Brazil, Canada, Chile, Mexico, New Zealand, Portugal</td>
<td>4</td>
</tr>
<tr>
<td>Albania, Bosnia and Herzegovina, Bulgaria, Costa Rica, Cyprus, Ecuador, Finland, Iran, Japan, Kuwait, Lithuania, Luxembourg, Norway, Philippines, Quatar, Sri Lanka, Sudan, Thailand, Trinidad &amp; Tobago, USA, Zimbabwe</td>
<td>3</td>
</tr>
</tbody>
</table>

9 years of EAACI Knowledge Exam

Question pool continuously refreshed by EAACI Task Force Output

360 candidates from 50 countries since 2008

Reduced fees with collaboration EAACI-UEMS

New: Online application system

Application is open each year from February to April
EAACI-UEMS Knowledge Exam - 2016

• 51 candidates took the exam, representing 22 countries.
• Includes countries as far away as India, Japan, Thailand, Mexico and South Africa
• In 2015 53 candidates took the exam. 44 participants passed and 9 failed
Task Forces

73 ongoing or new Task Forces in 2016, worth over 800k EUR

Budget application process for 2017 opens in summer
➢ An Email will be sent to IGs and Sections at the end of June
➢ Online application closes mid September
➢ Budgets will be approved in November

→ Get involved in your IG or Section! IG/Section Business Meetings are a good opportunity
Position Papers

• 14 Position Papers approved since June 2015

• 2 Position Papers currently in Review
All EAACI events are CME accredited
The EBAACI (EAACI & UEMS members) is in charge of evaluating all incoming requests for accreditation
➢ 23 events accredited in 2015
➢ So far 6 accredited in 2016

New agreement with UEMS is underway to include also distance learning and possibly review activities
Projects 2016

➢ Update paper “Allergy Services in Europe” by Bonini et al from 2006

➢ Develop Criteria for training and training facilities in a subspecialty of Allergy
Past Allergy Schools since June 2015

e-PAD: EAACI Practical Allergy Diagnosis
Moscow, Russia, 27 – 29 August 2015

Food Allergy Training Course
El Escorial, Spain, 24 – 26 September 2015

14th EAACI Immunology Winter School
Pocol, Italy, 4 - 7 February 2016

Allergy School on AIT
7 – 9 April 2016, Rungstedgaard, Denmark
Upcoming Allergy Schools

Drug Allergy in Children
Belgrade, Serbia, 22 – 24 September 2016

15th EAACI Immunology Winter School
Sierra Nevada, Spain, 26 - 29 January 2017

Eosinophilic Esophagitis
Vlaardingen, Netherlands, 16 – 18 March 2017
• A new and interactive event format

• Cover basic, clinical and translational topics, targeting specialists in a particular field.

• Master Class requires a higher level of professional experience and offers an excellent platform for exchange of knowledge.

• Sessions have a workshop character, making them as interactive as possible.

• The group size is limited to a maximum of 50 attendees to allow for active discussions.
APPROVAL

of

VICE-PRESIDENTS’ REPORT
CONCLUSION

QUESTIONS?

COMMENTS?